ADC Therapeutics (ADCT) Non-Current Debt (2020 - 2026)
ADC Therapeutics (ADCT) posted Non-Current Debt of $111.0 million for Q1 2026, down 1.25% sequentially from $112.5 million in Q4 2025, and down 2.44% YoY from $113.8 million in Q1 2025.
ADC Therapeutics (ADCT) Non-Current Debt (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Non-Current Debt for 7 years, with the latest figure at $111.0 million in Q1 2026.
- Quarterly Non-Current Debt fell 2.44% year-over-year to $111.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.0 million (down 2.44% YoY) and the FY2025 annual result came in at $112.5 million, down 1.04% from the prior year.
- Non-Current Debt eased to $111.0 million in Q1 2026 per ADCT's latest filing, from $112.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $115.2 million in Q3 2025 and troughed at $88.4 million in Q1 2022.
- A 5-year average of $106.5 million and a median of $112.5 million in 2025 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2026: Non-Current Debt surged 147.16% in 2022, then dropped 2.44% in 2026.
- Over 5 years, Non-Current Debt stood at $109.7 million in 2022, then climbed by 2.75% to $112.7 million in 2023, then increased by 0.8% to $113.6 million in 2024, then declined by 1.04% to $112.5 million in 2025, then dropped by 1.25% to $111.0 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $111.0 million, $112.5 million, and $115.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | 110.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.44 Mn |
| Mar 31, 2026 | 111.04 Mn |
| Dec 31, 2025 | 112.45 Mn |
| Sep 30, 2025 | 115.21 Mn |
| Jun 30, 2025 | 114.50 Mn |
| Mar 31, 2025 | 113.82 Mn |
| Dec 31, 2024 | 113.63 Mn |
| Sep 30, 2024 | 114.20 Mn |
| Jun 30, 2024 | 113.70 Mn |
| Mar 31, 2024 | 113.23 Mn |
| Dec 31, 2023 | 112.73 Mn |
| Sep 30, 2023 | 97.71 Mn |
| Jun 30, 2023 | 97.40 Mn |
| Mar 31, 2023 | 97.01 Mn |
| Dec 31, 2022 | 109.71 Mn |
| Sep 30, 2022 | 96.73 Mn |
| Jun 30, 2022 | 89.84 Mn |
| Mar 31, 2022 | 88.42 Mn |
| Dec 31, 2021 | 87.15 Mn |
| Sep 30, 2021 | 85.88 Mn |